Celebrating another banner week for New Jersey with Celgene completing the purchase of its second facility in Summit, Nestlé Health Science expanding its footprint in the Garden State and the naming of two New Jersey Nobel laureates at Princeton and Drew Universities. This all comes on the heels of another FDA drug approval for a New Jersey company!
BioNJ Member Celgene Corporation has completed its purchase of the former Merck & Co. research and development complex in Summit, giving a new lease on life to the 1.3 million-square-foot campus as the biotech giant continues its expansion in the city.
In a vote of confidence that New Jersey is a premier destination for life sciences companies, Nestlé Health Science will open an 180,000-square-foot R&D facility at the Center of Excellence campus on Route 202/206 for the development of nutrition-based therapies, becoming the latest tenant at the 110-acre site once occupied by Sanofi U.S. The facility will include laboratories, a pilot manufacturing plant and offices for the company’s commercialization and front office staff.
Congratulations to BioNJ Member Taiho Pharmaceutical for the FDA approval of LONSURF® (trifluridine and tipiracil) for refractory metastatic colorectal cancer.
Congratulations to Dr. William Campbell, a scientist and associate fellow at Drew University, for winning the Nobel Prize for Medicine and Angus Deaton, a professor at BioNJ Member Princeton University, for being awarded the Nobel Prize in Economics. These are two more shining examples of New Jersey’s world class education system!
Join us for BioNJ’s Entrepreneurship Program, Mission Possible: Non-Traditional Avenues to Funding Your Start-Up. Taking place on Thursday, October 29, at BioNJ Preferred Member Rutgers University, you’ll hear presentations and case studies on non-traditional and unique funding opportunities. Register now.
Click here to read this week’s Weekender.